AIM

Company Overview — What Does AIM ImmunoTech Inc. Do?

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. AIM ImmunoTech Inc. (AIM) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Thomas K. Equels and employs approximately 20 people, headquartered in OCALA, Florida. With a market capitalization of $2M, AIM is one of the notable companies in the Healthcare sector.

AIM ImmunoTech Inc. (AIM) Stock Rating — Avoid (April 2026)

As of April 2026, AIM ImmunoTech Inc. receives a Avoid rating with a composite score of 23.1/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.AIM ranks #4,327 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AIM ImmunoTech Inc. ranks #791 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AIM Stock Price and 52-Week Range

AIM ImmunoTech Inc. (AIM) currently trades at $0.53. The stock gained $0.01 (2.9%) in the most recent trading session. The 52-week high for AIM is $20.35, which means the stock is currently trading -97.4% from its annual peak. The 52-week low is $0.06, putting the stock 741.7% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is AIM Overvalued or Undervalued? — Valuation Analysis

AIM ImmunoTech Inc. (AIM) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 0.44x, compared to the Healthcare sector average of 23.63x — a discount of 98%. The price-to-sales ratio is 43.66x, compared to 1.66x for the average Healthcare stock.

At current multiples, AIM ImmunoTech Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

AIM ImmunoTech Inc. Profitability — ROE, Margins, and Quality Score

AIM ImmunoTech Inc. (AIM) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -233.2% versus the sector average of -33.1%.

On a margin basis, AIM ImmunoTech Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -13860.0% (sector: -66.1%). Net profit margin stands at -14383.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -48.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AIM Debt, Balance Sheet, and Financial Health

Balance sheet data for AIM is evaluated through our stability factor. The current ratio is 0.53x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $4M. Cash and equivalents stand at $2M.

AIM has a beta of -47.93, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for AIM ImmunoTech Inc. is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

AIM ImmunoTech Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, AIM ImmunoTech Inc. reported revenue of $102,000 and earnings per share (EPS) of $-8.62. Net income for the quarter was $-13M. Gross margin was 100.0%. Operating income came in at $-13M.

In FY 2025, AIM ImmunoTech Inc. reported revenue of $88,000 and earnings per share (EPS) of $-8.62. Net income for the quarter was $-14M. Revenue grew -48.2% year-over-year compared to FY 2024. Operating income came in at $-12M.

In Q3 2025, AIM ImmunoTech Inc. reported revenue of $26,000 and earnings per share (EPS) of $1.57. Net income for the quarter was $-3M. Revenue grew -25.7% year-over-year compared to Q3 2024. Operating income came in at $-2M.

In Q2 2025, AIM ImmunoTech Inc. reported revenue of $25,000 and earnings per share (EPS) of $-3.68. Net income for the quarter was $-3M. Gross margin was 100.0%. Revenue grew -50.0% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, AIM ImmunoTech Inc. has demonstrated a growth trajectory, with revenue expanding from $50,000 to $102,000. Investors analyzing AIM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AIM Dividend Yield and Income Analysis

AIM ImmunoTech Inc. (AIM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AIM Momentum and Technical Analysis Profile

AIM ImmunoTech Inc. (AIM) has a momentum factor score of 18/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

AIM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AIM ImmunoTech Inc. (AIM) ranks #791 out of 838 stocks based on the Blank Capital composite score. This places AIM in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AIM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AIM vs S&P 500 (SPY) comparison to assess how AIM ImmunoTech Inc. stacks up against the broader market across all factor dimensions.

AIM Next Earnings Date

No upcoming earnings date has been announced for AIM ImmunoTech Inc. (AIM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AIM? — Investment Thesis Summary

The quantitative profile for AIM ImmunoTech Inc. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Momentum is weak at 18/100, a headwind for near-term performance. High volatility (stability score 26/100) increases portfolio risk.

In summary, AIM ImmunoTech Inc. (AIM) earns a Avoid rating with a composite score of 23.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AIM stock.

Related Resources for AIM Investors

Explore more research and tools: AIM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AIM head-to-head with peers: AIM vs AZN, AIM vs SLGL, AIM vs VMD.